From laboratory to arm – how the Oxford vaccine is created
A team combatting Disease X in Oxford, a glass vial plant in Wales, and safety checks in Hertfordshire
6 January 2021 • 1:36pm
Some 530,000 doses of the vaccine became available across the UK from January 4, with vulnerable groups already identified as the priority for immunisation
On Monday, six NHS Trusts began administering the Oxford-AstraZeneca vaccine to vulnerable people. It followed months of trials in which 11,500 volunteers from the UK and Brazil received the vaccine, and which found it to be 70.4 per cent effective on average.
Dialysis patient Brian Pinker, 82, was the first person to receive his jab in the UK, at Oxford University Hospitals NHS Foundation Trust s Churchill Hospital, saying he was so pleased to be getting the Covid vaccine and really proud that it is one that was invented in Oxford .
25 Days That Changed the World: How Covid-19 Slipped Chinaâs Grasp
The most famous doctor in China was on an urgent mission.
Celebrated as the hero who helped uncover the SARS epidemic
17 years ago, Dr. Zhong Nanshan, now 84, was under orders to rush to Wuhan, a city in central China, and investigate a strange new coronavirus. His assistant photographed the doctor on the night train, eyes closed in thought, an image that would later rocket around China and burnish Dr. Zhongâs reputation as the nationâs medic riding to the rescue.
Chinaâs official history now portrays Dr. Zhongâs trip as the cinematic turning point in an ultimately triumphant war against Covid-19, when he discovered the virus was spreading dangerously and sped to Beijing to sound the alarm. Four days later, on Jan. 23, Chinaâs leader, Xi Jinping, sealed off Wuhan.
Reading the clues from Covaxin early trial data hindustantimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hindustantimes.com Daily Mail and Mail on Sunday newspapers.
Search jobs 24-Dec-2020 Innovative drug, Carrimycin, Receives FDA Approval for International, Multi-country Phase III Clinical Trial for the treatment of severe COVID-19 in hospitalized patients
Shenyang Tonglian Group Co., Ltd. announces FDA approval for a randomized, multicenter, placebo-controlled, double-blind clinical study of the safety and efficacy of Carrimycin for the treatment of severe COVID-19 in hospitalized patients
International 300-patient study, to start in January 2021 and run for ~6 months in the USA, Mexico, Brazil, Philippines, Ukraine, Argentina, Peru, Colombia and India
Carrimycin is an innovative drug marketed in China, shown in China to have a positive impact on outcome for hospitalized COVID-19 patients with potential significant advantages